Advanced Search


Study ID Status Title Patient Level Data
113203 Completed A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray 110 mcg in the treatment in the treatment of uncomplicated acute rhinosinusitis in adults and adolescents >= 12 years of age
113208 Completed A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 and GW642444 as monotherapies and concurrently in healthy Japanese subjects Study Listed on
113209 Completed A randomised, double-blind, placebo-controlled, dose ascending,3-way crossover study to assess the pharmacokinetics, safety andtolerability of repeat inhaled doses of nebulised GW870086X inhealthy adult male volunteers. Study Listed on
113211 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study Evaluating the Efficacy and Safety of the Neurokinin-1 Receptor Antagonist Orvepitant (GW823296) in Post Traumatic Stress Disorder (PTSD)
113214 Completed An open-label, five-way, partially randomized crossover study to evaluate the regional gastrointestinal absorption of retigabine in healthy volunteers Study Listed on
113215 Completed A two part study to assess the pharmacokinetic performance of three retigabine modified release (MR) formulations after single dose and to assess the pharmacokinetics and tolerability of titration with retigabine MR Study Listed on
113220 Relinquished An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma
113221 Completed A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects with Colorectal Cancer and Hepatic Metastases Study Listed on
113222 Terminated A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Study Listed on
113237 Completed Immunogenicity and safety study of a GlaxoSmithKline Biologicals’ candidate influenza vaccine GSK2321138A in healthy children Study Listed on
113261 Completed Gender vs. Fed/Fasted State vs. Capsule/Liquid Suspension Formulation Study Study Listed on
113263 Terminated A multi-center, randomized, double-blind, parallel-group study to compare the efficacy and safety of fixed-dose Rosiglitazone/Glimepiride combination therapy with Glimepiride monotherapy for 24 weeks in drug naive subjects with type 2 diabetes
113264 Completed Immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline Biologicals’ GSK2036874A vaccine in healthy toddlers Study Listed on
113266 Completed Evaluation of immunological persistence following 3-dose priming with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine in study NCT00808444 and safety and immunogenicity following a booster dose of the same vaccine Study Listed on
113267 Completed Drug Use Investigation of Flutide in Adult Patients with Bronchial Asthma
113268 Completed Drug use investigation for Relenza
113269 Completed Acceptability of Hepatitis B vaccination among General Population
113272 Completed Post Marketing Surveillance of Zyban-SR (Bupropion hydrochloride) in the Treatment of Nicotine Dependence Among Indian Patients
113275 Completed Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children Study Listed on
113284 Terminated Open-label, multiple dose study to evaluate the parmacokinetics, safety and tolerability of ezogabine/retigabine as adjunctive treatment in subjects aged from 12 years to less than 18 years with partial onset seizures or Lennox-Gastaut syndrome Study Listed on
113287 Completed An open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of retigavine given as the Market Image tablet compared to the retigavine clinical trial tablets. Study Listed on
113299 Completed A randomised, single-blind, placebo-controlled, study toevaluate the safety, tolerability, pharmacodynamics andpharmacokinetics of repeat subcutaneous administration ofotelixizumab in subjects with rheumatoid arthritis Study Listed on
113310 Completed A multi-center, randomized, double-blind, placebo-controlled, five period cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of GW642444 administered via a novel dry powder inhaler (NDPI) in subjects ≥18 years of age with persistent asthma Study Listed on
113312 Completed A Randomized, Placebo-Controlled, Double-Blind, Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days Study Listed on
113314 Completed Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.